Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.

摘要: A human medulloblastoma (BN-2) and a glioblastoma (BN-3) which were previously established in nude mice used to determine the effect of combined modality therapy with gamma-radiation, three chemotherapeutic agents, procarbazine, 1,4-cyclohexadiene-1,4-dicarbamic acid, 2,5-bis(1-aziridinyl)-3,6-dioxo diethylester (AZQ), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). The tumor cells grown tissue culture implanted intracranially right cerebral hemisphere NIH Swiss depth 3 mm. randomized, treatment was started days after implantation. Procarbazine AZQ injected i.p. every 5 for treatments. BCNU one time single treatment. Radiation localized head. 60Co unit irradiation at rate 125 rads/min Ten experiments performed using six nine per group different drug-radiation dose combinations. drug ranged from 400 500 mg/kg/injection 7.5 AZQ, 10 20 BCNU. radiation 320 1050 rads/mouse (whole head). day death recorded each animal, mean calculate percentage increase life span (ILS) compared untreated control group. Chemotherapy alone produced minimal effect, while effects 640 rads progressively positive 800 rads. When combination xenograft procarbazine used, ILS significantly increased all four experiments, ranging 25 41%, superior single-modality but 1050-rad treatment, where it showed an equal effect. no tumor. Combination significant ILSs 105 119% mg/kg doses 540 rads, respectively. mouse-human model found be useful studies should give valuable information experimental design pilot Phase III clinical against variety brain tumors.